STEVEN GIBSON: Open Payments
NPI 1336146422 · JEFFERSONVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,131 in 50 payments from 8 companies in 2025. Trend: 2023 $891 · 2024 $973 · 2025 $1,131
Food & beverage: $1,131
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 14 | $370 |
| Otsuka America Pharmaceutical, Inc. | 11 | $227 |
| Lundbeck LLC | 9 | $183 |
| Alkermes, Inc. | 7 | $140 |
| Teva Pharmaceuticals USA, Inc. | 4 | $102 |
| E.R. Squibb & Sons, L.L.C. | 3 | $69 |
| Janssen Pharmaceuticals, Inc | 1 | $27 |
| Luye Pharma (USA) Ltd. | 1 | $14 |
Products named: ABILIFY ASIMTUFII, INGREZZA, ARISTADA, UZEDY, COBENFY, SPRAVATO, ABILIFY MAINTENA, ERZOFRI EXTENDED-RELEASE.
Industry payments across IN — which companies pay providers there.
